Equities

SciBase Holding AB (publ)

SciBase Holding AB (publ)

Actions
  • Price (SEK)0.394
  • Today's Change-0.002 / -0.51%
  • Shares traded800.00
  • 1 Year change-51.36%
  • Beta1.6543
Data delayed at least 15 minutes, as of Nov 22 2024 11:22 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SciBase Holding AB is a Sweden-based company engaged in the medical equipment industry. The Company specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.

  • Revenue in SEK (TTM)26.87m
  • Net income in SEK-64.21m
  • Incorporated2008
  • Employees27.00
  • Location
    SciBase Holding AB (publ)Landsvagen 39SUNDBYBERG 17263SwedenSWE
  • Phone+46 841062000
  • Fax+46 86152224
  • Websitehttps://scibase.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Phase Holographic Imaging PHI AB9.12m-21.81m52.19m14.00------5.72-0.8695-0.86950.3634-0.02730.23730.65981.18651,571.40-56.73-62.04-88.25-79.1671.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--22.76--
Clinical Laserthermia Systems AB18.63m-64.20m52.65m7.00--0.862--2.83-7.93-7.932.054.390.2657.625.22---92.16-123.49-103.14-312.95-175.42-1,084.16-347.76-1,625.032.39-11.710.0077--31.9935.55-12.92--18.26--
iZafe Group AB6.29m-31.99m55.00m7.00--3.53--8.75-0.1319-0.13190.02590.05670.16023.2512.26898,285.70-81.49-52.17-100.43-69.40-116.33-198.20-508.73-487.500.4406-43.460.3159--149.93-24.79-36.76---41.66--
ScandiDos AB61.35m-9.67m74.80m26.00--2.14--1.22-0.2068-0.20681.260.7660.81841.316.881,978,871.00-12.90-12.60-23.54-21.7650.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
Ortivus AB77.96m-17.79m81.55m32.00--33.49--1.05-0.4016-0.40161.760.05380.9036--23.271,949,050.00-20.62-2.41-41.25-4.6336.3842.46-22.82-1.770.4251-7.580.9447---19.5510.00-409.66--67.43--
Kontigo Care AB30.11m990.00k85.24m10.0090.852.0118.612.830.02930.02931.041.330.6232--8.46--2.05-0.42142.80-0.619566.7766.313.29-0.5205--12.010.0922--1.8016.95-92.68--44.94--
SciBase Holding AB (publ)26.87m-64.21m86.94m27.00--2.29--3.24-0.4237-0.42370.16650.17260.38510.72223.30995,185.20-92.01-68.63-122.20-87.7772.2961.28-238.95-300.202.44-14.840.00--29.9327.50-28.75--5.15--
Dignitana AB86.49m-25.27m96.65m29.00--9.88--1.12-0.3268-0.32681.130.12151.742.7615.193,203,482.00-50.91-42.21-122.38-68.9169.5666.09-29.22-57.290.5202-9.970.609--17.9020.5922.52---15.31--
Episurf Medical AB12.80m-79.70m98.17m26.00--0.9679--7.67-0.2072-0.20720.03010.15580.1059--5.57457,142.80-66.09-47.46-75.45-52.01-----624.22-1,019.296.17--0.0296--53.6219.78-22.64---0.4158--
Immunovia AB (publ)885.00k-116.12m98.43m10.00--2.68--111.22-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Observe Medical ASA-99.90bn-99.90bn101.16m5.00--0.646----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Redsense Medical AB (publ)23.77m-3.98m103.93m5.00--3.24--4.37-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Iconovo AB2.92m-40.21m106.55m28.00--0.7154--36.54-2.74-2.740.1967.020.0215--1.14100,561.70-29.61-25.43-33.16-28.24635.97134.57-1,378.66-215.16---1,179.070.0668---58.65-9.884.71--34.70--
Luxbright AB4.20m-22.23m110.43m10.00--3.71--26.28-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Vo2 Cap Holding AB (publ)348.03m-55.15m112.06m94.00--0.6226--0.322-0.9759-0.97596.463.160.7992--8.213,378,952.00-12.66-0.2564-17.29-0.383935.7823.36-15.84-0.2409---6.950.1429---26.0985.65-57.92---17.96--
BibbInstruments AB0.00-12.21m116.81m4.00--3.63-----0.4477-0.44770.001.100.00-------34.78-39.57-36.66-42.71--59.36---8,032.404.41--0.00------2.72---1.94--
Data as of Nov 22 2024. Currency figures normalised to SciBase Holding AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 31 Oct 202430.31k0.01%
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.